Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Comment by wildbird1on Aug 26, 2023 12:45pm
260 Views
Post# 35606752

RE:RE:New Deal for Adstiladrin

RE:RE:New Deal for Adstiladrin
enriquesuave wrote: Basically paying upfront  $500 Million for 5.1% and up to 8 % of sales of Adstiladrin over next 10 years or so.  That means they expect sales of up to $1 Billion per year.  Crazy, our turn will hopefully come soon.


enriquesuave, very good catch.

Let's see the difference between Adstiladrin & Ruvidar(TLD-1433).

CR%...
Adstiladrin 24%CR at 12 months.
Ruvidar 36%CR(and increasing) at 12 months.

Cost...
Adstiladrin for one year treatment cost $268kUS($364kCan).
Ruvidar cost $200k.US($300k.Can) for a one and done treatment.
For BCG-Resistant patients(and doctors) the choice will be easy.

enriquesuave you said " TLT should get double" I say double is a minimum.

In conclusion;
$500 millionUS for a treatment(Adstiladrin) that has a lower efficacy and cost more than Ruvidar.

I salivate at the idea of a big pharma deal for Ruvidar.


<< Previous
Bullboard Posts
Next >>